MA27500A1 - Prevention et traitement de la maladie d'alzheimer - Google Patents

Prevention et traitement de la maladie d'alzheimer

Info

Publication number: MA27500A1
Authority: MA; Morocco
Prior art keywords: inhibitor; alzheimer; disease; prevention; treatment
Prior art date: 2002-12-12

Application number

MA28329A

Other languages

English (en)

French (fr)

Inventor

Thierry Canton

Laurent Pradier

Jesus Benavides

Hubert Heuer

Hans-Ludwig Schaefer

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-12

Filing date

2005-06-10

Publication date

2005-08-01

2005-06-10 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2005-08-01 Publication of MA27500A1 publication Critical patent/MA27500A1/fr

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 2
230000002265 prevention Effects 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 abstract 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
229940121773 Secretase inhibitor Drugs 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

MA28329A 2002-12-12 2005-06-10 Prevention et traitement de la maladie d'alzheimer MA27500A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0215722A FR2848452B1 (fr)	2002-12-12	2002-12-12	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number	Publication Date
MA27500A1 true MA27500A1 (fr)	2005-08-01

Family

ID=32338722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28329A MA27500A1 (fr)	2002-12-12	2005-06-10	Prevention et traitement de la maladie d'alzheimer

Country Status (22)

Country	Link
EP (1)	EP1572174A1 (pl)
JP (1)	JP2006514063A (pl)
KR (1)	KR20050084250A (pl)
CN (1)	CN1726016A (pl)
AR (1)	AR042354A1 (pl)
AU (1)	AU2003296802A1 (pl)
BR (1)	BR0317280A (pl)
CA (1)	CA2507945A1 (pl)
CO (1)	CO5700712A2 (pl)
FR (1)	FR2848452B1 (pl)
HR (1)	HRP20050534A2 (pl)
MA (1)	MA27500A1 (pl)
MX (1)	MXPA05005556A (pl)
NO (1)	NO20053341L (pl)
NZ (1)	NZ540496A (pl)
PE (1)	PE20040770A1 (pl)
PL (1)	PL377110A1 (pl)
RS (1)	RS20050420A (pl)
RU (1)	RU2005121909A (pl)
TW (1)	TW200503707A (pl)
WO (1)	WO2004062652A1 (pl)
ZA (1)	ZA200504656B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en)	2003-11-03	2009-04-30	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en)	2004-02-05	2012-01-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
EP1812007B1 (en)	2004-11-02	2011-09-07	Northwestern University	Pyridazine compounds and methods
EP2015750A2 (en)	2006-04-28	2009-01-21	Northwestern University	Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) *	2007-05-22	2019-07-10	Otsuka Pharmaceutical Co., Ltd.	A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
MX363161B (es) *	2011-10-28	2019-03-13	Lumena Pharmaceuticals Inc	Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2040996A1 (en) *	1990-05-02	1991-11-03	Robert L. Albright	Composition and method for controlling cholesterol
CA2104594C (en) *	1991-02-22	2004-05-11	Howard K. Shapiro	Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3649697A (en) *	1996-06-27	1998-01-14	G.D. Searle & Co.	Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) *	1997-12-18	1999-11-16	Forbes Medi-Tech, Inc.	Method of preventing and delaying onset of Alzheimer's disease and composition therefor
AU762124B2 (en) *	1998-01-28	2003-06-19	Warner-Lambert Company	Method for treating Alzheimer's disease
US6080778A (en) *	1998-03-23	2000-06-27	Children's Medical Center Corporation	Methods for decreasing beta amyloid protein
DE19825804C2 (de) *	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
US20010028895A1 (en) *	2000-02-04	2001-10-11	Bisgaier Charles L.	Methods of treating alzheimer's disease
US20020028826A1 (en) *	2000-06-15	2002-03-07	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
TWI329111B (en) *	2002-05-24	2010-08-21	X Ceptor Therapeutics Inc	Azepinoindole and pyridoindole derivatives as pharmaceutical agents

2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/fr not_active Expired - Fee Related
2003
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/sr unknown
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/es not_active Application Discontinuation
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/ru not_active Application Discontinuation
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/es not_active Application Discontinuation
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/ja not_active Abandoned
- 2003-12-10 CA CA002507945A patent/CA2507945A1/fr not_active Abandoned
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/fr not_active Ceased
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/pt not_active IP Right Cessation
- 2003-12-10 AR ARP030104540A patent/AR042354A1/es not_active Application Discontinuation
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/xx not_active Application Discontinuation
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/zh active Pending
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/ko not_active Withdrawn
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 PL PL377110A patent/PL377110A1/pl not_active Application Discontinuation
- 2003-12-10 EP EP03815109A patent/EP1572174A1/fr not_active Withdrawn
- 2003-12-11 TW TW092134949A patent/TW200503707A/zh unknown
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/fr unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20053341D0 (no)	2005-07-08
NZ540496A (en)	2008-04-30
AU2003296802A1 (en)	2004-08-10
PE20040770A1 (es)	2004-12-10
HRP20050534A2 (en)	2006-11-30
CO5700712A2 (es)	2006-11-30
CN1726016A (zh)	2006-01-25
WO2004062652A1 (fr)	2004-07-29
KR20050084250A (ko)	2005-08-26
MXPA05005556A (es)	2005-07-26
ZA200504656B (en)	2006-08-30
FR2848452A1 (fr)	2004-06-18
JP2006514063A (ja)	2006-04-27
EP1572174A1 (fr)	2005-09-14
NO20053341L (no)	2005-09-07
AR042354A1 (es)	2005-06-15
CA2507945A1 (fr)	2004-07-29
FR2848452B1 (fr)	2007-04-06
BR0317280A (pt)	2005-11-08
TW200503707A (en)	2005-02-01
PL377110A1 (pl)	2006-01-23
RS20050420A (sr)	2007-04-10
RU2005121909A (ru)	2006-01-20

Publication	Publication Date	Title
TNSN01125A1 (fr)	2005-11-10	Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
GB0223040D0 (en)	2002-11-13	Therapeutic compounds
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
SI1509232T1 (sl)	2009-04-30	Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
EP1604664A4 (en)	2006-12-27	MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
WO2005004802A3 (en)	2005-09-22	N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN98155A1 (fr)	2005-03-15	Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
EP1910829A4 (en)	2009-04-22	PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGEN DISEASES
FR2840804B1 (fr)	2004-09-17	Systeme pour le traitement de l'obesite et implant pour un tel systeme
ATE368031T1 (de)	2007-08-15	Neue gamma secretase inhibitoren
EP1656359A4 (en)	2010-07-07	MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1771201A4 (en)	2011-01-19	COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE
IL229124A0 (en)	2013-12-31	Inhibitors with a mutant form of kit
MY133332A (en)	2007-11-30	Pyrrolidone derivatives as maob inhibitors
NO20053855L (no)	2005-11-21	1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
AU2003231252A1 (en)	2003-11-11	Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MA27500A1 (fr)	2005-08-01	Prevention et traitement de la maladie d'alzheimer
NO20065117L (no)	2006-11-07	Sammensetning omfattende en JNK inhibitor og syklosporin.
MXPA05009986A (es)	2005-11-04	Tratamiento de la enfermedad de alzheimer.
WO2002039122A3 (en)	2004-02-26	Methods for the identification and the treatment of cardiovascular disease
EP1488808A4 (en)	2007-05-23	Remedies for glomerular diseases
ATE423102T1 (de)	2009-03-15	4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
EP1726313A4 (en)	2008-04-09	MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS
WO2004028456A3 (en)	2004-06-17	Method and composition for treating neurodegenerative disorders
TW200612900A (en)	2006-05-01	The use of therapeutic and preventive action of l-3-n-butylphthalide on dementia, involving alzheimer's disease and vascular dementia